Vical Incorporated (VICL)’s Financial Results Comparing With scPharmaceuticals Inc. (NASDAQ:SCPH)

We are comparing Vical Incorporated (NASDAQ:VICL) and scPharmaceuticals Inc. (NASDAQ:SCPH) on their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vical Incorporated N/A 20.78 14.56M -0.67 0.00
scPharmaceuticals Inc. N/A 0.00 29.43M -1.59 0.00

Table 1 highlights Vical Incorporated and scPharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 demonstrates the return on assets, return on equity and net margins of Vical Incorporated and scPharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Vical Incorporated 0.00% -29.4% -27.6%
scPharmaceuticals Inc. 0.00% -36.7% -30.6%


Vical Incorporated has a Current Ratio of 18.4 and a Quick Ratio of 18.4. Competitively, scPharmaceuticals Inc.’s Current Ratio is 8.5 and has 8.5 Quick Ratio. Vical Incorporated’s better ability to pay short and long-term obligations than scPharmaceuticals Inc.

Insider & Institutional Ownership

The shares of both Vical Incorporated and scPharmaceuticals Inc. are owned by institutional investors at 38.6% and 77.4% respectively. Insiders held roughly 0.97% of Vical Incorporated’s shares. Insiders Comparatively, held 0.1% of scPharmaceuticals Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Vical Incorporated -1.41% -3.39% 15.15% -14.29% -32.94% -3.39%
scPharmaceuticals Inc. -5.12% 41.94% 6.34% -25.11% -75.38% -6.38%

For the past year Vical Incorporated has stronger performance than scPharmaceuticals Inc.


Vical Incorporated beats on 7 of the 7 factors scPharmaceuticals Inc.

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It is developing various DNA-based vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy. The company also engages in contract manufacturing of plasmid investigational products for various clients. It has collaborations with Astellas to develop and commercialize certain products, including ASP0113 for the control and prevention of CMV infection in immunocompromised patients; and Merial for use of the companyÂ’s core DNA delivery technology in a therapeutic vaccine designed to aid in extending survival time of dogs with oral melanoma. It also has a license agreement with Astellas to develop and commercialize novel antifungal candidate. The company was founded in 1987 and is headquartered in San Diego, California.

scPharmaceuticals Inc., biopharmaceutical company, engages in the development and commercialization of transformative pharmaceutical products. The company's under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.